Alessia Mennitto

6PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 28, 2026
Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Orazio Caffo, Umberto Basso, Antonello Veccia

|Jan 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).

Marco Stellato, Sebastiano Buti, Marco Maruzzo

|Apr 12, 2022
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.

Carlo Cattrini, Orazio Caffo, Ugo De Giorgi

|Nov 05, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).

Alessia Mennitto, Emma Zattarin, Massimo Di Maio

|Jan 21, 2021
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.

A Mennitto, E Verzoni, F Cognetti

|Nov 06, 2020
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.

Raffaele Ratta, Elena Verzoni, Alessia Mennitto

Pageof 1

Frequent Collaborators

3 joint publications

Giuseppe Procopio

2 joint publications

Elena Verzoni

2 joint publications

Ugo De Giorgi

2 joint publications

Franco Morelli